Active Ingredient: Interferon, alfa-2b
For this indication, competent medicine agencies globally authorize below treatments:
Subcutaneous
4,000,000 - 5,000,000 [iU]
From 4,000,000 To 5,000,000 [iU] once every day
The recommended dose of interferon alpha-2b is 4 to 5 million IU/m² administered daily subcutaneously. Some patients have been shown to benefit from interferon alpha-2b 5 million IU/m² administered daily subcutaneously in association with cytarabine (Ara-C) 20 mg/m² administered daily subcutaneously for 10 days per month (up to a maximum daily dose of 40 mg). When the white blood cell count is controlled, administer the maximum tolerated dose of interferon alpha-2b (4 to 5 million IU/m² daily) to maintain haematological remission.
Interferon alpha-2b treatment must be discontinued after 8 to 12 weeks of treatment if at least a partial haematological remission or a clinically meaningful cytoreduction has not been achieved.
Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.
